- Home
- GH vs SIGI Comparison
GH vs SIGI Comparison
Compare GH & SIGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- SIGI
- Stock Information
- Founded
- GH 2011
- SIGI 1926
- Country
- GH United States
- SIGI United States
- Employees
- GH N/A
- SIGI N/A
- Industry
- GH Medical Specialities
- SIGI Property-Casualty Insurers
- Sector
- GH Health Care
- SIGI Finance
- Exchange
- GH Nasdaq
- SIGI Nasdaq
- Market Cap
- GH 5.5B
- SIGI 5.1B
- IPO Year
- GH 2018
- SIGI N/A
- Fundamental
- Price
- GH $40.62
- SIGI $88.02
- Analyst Decision
- GH Strong Buy
- SIGI Hold
- Analyst Count
- GH 21
- SIGI 8
- Target Price
- GH $52.81
- SIGI $94.00
- AVG Volume (30 Days)
- GH 2.3M
- SIGI 390.3K
- Earning Date
- GH 04-30-2025
- SIGI 07-17-2025
- Dividend Yield
- GH N/A
- SIGI 1.73%
- EPS Growth
- GH N/A
- SIGI N/A
- EPS
- GH N/A
- SIGI 3.68
- Revenue
- GH $773,996,000.00
- SIGI $4,981,891,000.00
- Revenue This Year
- GH $23.05
- SIGI $6.05
- Revenue Next Year
- GH $21.40
- SIGI $7.43
- P/E Ratio
- GH N/A
- SIGI $23.91
- Revenue Growth
- GH 28.20
- SIGI 13.30
- 52 Week Low
- GH $20.14
- SIGI $78.13
- 52 Week High
- GH $52.92
- SIGI $103.56
- Technical
- Relative Strength Index (RSI)
- GH 48.45
- SIGI 49.88
- Support Level
- GH $37.73
- SIGI $85.78
- Resistance Level
- GH $39.63
- SIGI $88.40
- Average True Range (ATR)
- GH 1.60
- SIGI 2.01
- MACD
- GH -0.01
- SIGI -0.14
- Stochastic Oscillator
- GH 60.00
- SIGI 51.75
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About SIGI Selective Insurance Group Inc.
Selective Insurance Group Inc is a regional property-casualty insurer based in New Jersey, with its operations focused in the New York metropolitan area. Since 1977, Selective has focused its sales efforts on small businesses, offering commercial products that include workers' compensation, general liability, property, and auto insurance. Selective also has a small personal insurance segment (under 20% of total premiums), selling auto and homeowner's coverage.